Literature DB >> 7442088

Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.

U Abshagen, W Kösters, B Kaufmann, P D Lang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7442088     DOI： 10.1007/bf01477001

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  10 in total

1.  [Dose-effects studies with bezafibrate in patients with hypercholesterolemia and hypertriglyceridemia (author's transl)].

Authors:  O Adam; G Wolfram; P D Lang; N Zöllner
Journal:  MMW Munch Med Wochenschr       Date:  1979-03-02

2.  One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.

Authors:  A G Olsson; P D Lang
Journal:  Atherosclerosis       Date:  1978-12       Impact factor: 5.162

3.  Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.

Authors:  A G Olsson; S Rössner; G Walldius; L A Carlson; P D Lang
Journal:  Atherosclerosis       Date:  1977-07       Impact factor: 5.162

4.  Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia.

Authors:  A G Olsson; P D Lang
Journal:  Atherosclerosis       Date:  1978-12       Impact factor: 5.162

5.  Clofibrate disposition in renal failure and acute and chronic liver disease.

Authors:  R Gugler; J W Kürten; C J Jensen; U Klehr; J Hartlapp
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

6.  A gas chromatographic method for the determination of bezafibrate in serum and urine.

Authors:  R Endele
Journal:  J Chromatogr       Date:  1978-07-21

7.  Disposition pharmacokinetics of bezafibrate in man.

Authors:  U Abshagen; W Bablok; K Koch; P D Lang; H A Schmidt; M Senn; H Stork
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

8.  [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].

Authors:  H R Arntz; U H Klemens; L J Vollmar; P D Lang
Journal:  Med Klin       Date:  1978-12-08

9.  [Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)].

Authors:  P Wahl; C Hasslacher; P D Lang; J Vollmar
Journal:  Dtsch Med Wochenschr       Date:  1978-08-04       Impact factor: 0.628

10.  Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.

Authors:  U Abshagen; S Spörl-Radun; J Marinow
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953
  10 in total
  10 in total

1.  Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients.

Authors:  G Neugebauer; D Platt; T Vömel; W Lösch
Journal:  Klin Wochenschr       Date:  1988-03-15

2.  Acute muscular syndrome after bezafibrate.

Authors:  K D Bock
Journal:  Klin Wochenschr       Date:  1981-12-01

3.  [Rhabdomyolysis with acute renal failure due to bezafibrate].

Authors:  H Heidemann; K D Bock
Journal:  Klin Wochenschr       Date:  1981-04-15

4.  [Fat and renal failure--therapeutic aspects].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-08

Review 5.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

6.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

7.  [Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function].

Authors:  K W Rumpf; M Barth; M Blech; H Kaiser; I Koop; R Arnold; F Scheler
Journal:  Klin Wochenschr       Date:  1984-04-16

Review 8.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

9.  Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.

Authors:  P Anderson; H E Norbeck
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.

Authors:  Koutaro Yokote; Shizuya Yamashita; Hidenori Arai; Eiichi Araki; Hideki Suganami; Shun Ishibashi; On Behalf Of The K-Study Group
Journal:  Int J Mol Sci       Date:  2019-02-06       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.